Evolus (NASDAQ:EOLS) Upgraded to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Evolus (NASDAQ:EOLS) from a hold rating to a buy rating in a research report sent to investors on Saturday morning.

Several other equities research analysts have also recently commented on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Evolus in a research note on Monday, December 22nd. BTIG Research reaffirmed a “buy” rating and set a $13.00 price target on shares of Evolus in a research note on Wednesday. Mizuho set a $15.00 price objective on shares of Evolus in a report on Wednesday, February 4th. HC Wainwright cut their price objective on shares of Evolus from $20.00 to $13.00 and set a “buy” rating on the stock in a research report on Tuesday, February 3rd. Finally, Needham & Company LLC restated a “hold” rating on shares of Evolus in a report on Wednesday, December 24th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $16.00.

Evolus Price Performance

EOLS opened at $5.53 on Friday. The company has a market capitalization of $359.78 million, a price-to-earnings ratio of -6.83 and a beta of 1.02. The business’s 50-day moving average price is $5.04 and its two-hundred day moving average price is $6.22. Evolus has a 1 year low of $4.09 and a 1 year high of $13.81.

Evolus (NASDAQ:EOLS) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported $0.00 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.09). The firm had revenue of $90.30 million during the quarter, compared to the consensus estimate of $89.58 million. Sell-side analysts anticipate that Evolus will post -0.61 earnings per share for the current fiscal year.

Insider Transactions at Evolus

In related news, insider David Moatazedi sold 10,539 shares of the stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $7.15, for a total transaction of $75,353.85. Following the completion of the transaction, the insider directly owned 354,388 shares of the company’s stock, valued at approximately $2,533,874.20. This represents a 2.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 5.90% of the company’s stock.

Institutional Investors Weigh In On Evolus

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Rhumbline Advisers boosted its holdings in shares of Evolus by 2.0% in the 2nd quarter. Rhumbline Advisers now owns 85,093 shares of the company’s stock valued at $784,000 after buying an additional 1,657 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Evolus by 5.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,289 shares of the company’s stock worth $400,000 after buying an additional 1,838 shares during the last quarter. Invesco Ltd. raised its position in Evolus by 7.5% during the second quarter. Invesco Ltd. now owns 34,283 shares of the company’s stock worth $316,000 after acquiring an additional 2,383 shares in the last quarter. Larson Financial Group LLC raised its position in Evolus by 136.6% during the fourth quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock worth $33,000 after acquiring an additional 2,837 shares in the last quarter. Finally, Manchester Capital Management LLC acquired a new stake in Evolus in the second quarter valued at $26,000. Institutional investors own 90.69% of the company’s stock.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.